When was DeepUll founded?

DeepUll was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is DeepUll located?

DeepUll is headquartered in Barcelona, Spain.

Who is the current CEO of DeepUll?

Jordi Carrer of DeepUll. They have also founded 1 company.

Is DeepUll a funded company?

DeepUll is a funded company, having raised a total of $92.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 07, 2020.

When was the latest funding round of DeepUll?

DeepUll's latest funding was a €***** Series C round on Apr 29, 2025, with participation from 10 investors. Its primary sector is Infectious Diseases. In Spain, the Infectious Diseases sector has seen $20.5M in funding in 2026 to date.

Where does DeepUll rank among its competitors?

DeepUll ranks 17th amongst 127 active competitors, of which 39 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Volition, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of DeepUll?

DeepUll's top competitors include OpGen, CytoVale and Volition. Among them, Volition secured the most recent funding round in March, 2026.

DeepUll - 2026 Company Profile, Team, Funding & Competitors

DeepUll is a series C company based in Barcelona (Spain), founded in 2020 by Jordi Carrer and Rafel Bru Gibert. It operates as a Developer of diagnostic technology for rapid identification of sepsis-causing pathogens. DeepUll has raised $92.5M in funding from investors like Kurma Partners, Panakes Partners and Columbus Venture Partners. The company has 127 active competitors, including 39 funded and 14 that have exited. Its top competitors include companies like OpGen, CytoVale and Volition.

Company Details

Developer of diagnostic technology for rapid identification of sepsis-causing pathogens. The company focuses on empowering hospitals with technology to identify pathogens and antibiotic resistance markers directly from blood. The goal is to provide reportable results in about one hour, addressing the critical need for faster diagnosis. The company's technology aims to improve patient outcomes through early and effective treatment.

Key Metrics

Founded Year

2020

Location

Barcelona, Spain

Stage

Series C

Total Funding

$92.5M in 5 rounds

Latest Funding Round

Series C, Apr 29, 2025, €*****

Investors

Kurma Partners & 15 more

Ranked

17^th among 127 active competitors

Similar Companies

CytoVale & 31 more

View DeepUll's full profile

DeepUll has raised a total funding of $92.5M over 5 rounds. Its first funding round was on Jul 07, 2020. Its latest funding round was a Series C round on Apr 29, 2025 for €*****. 10 investors participated in its latest round. DeepUll has 16 institutional investors.

Here is the list of recent funding rounds of DeepUll:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 29, 2025	8162451	Series C	4477325	4561511	3192290	6115453
Mar 01, 2023	8540514	Series B	5942372	8218274	4466436	9552442
Dec 13, 2022	8510215	Conventional Debt	3966410	3873648	3025307	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of DeepUll's funding rounds and investors

The founders of DeepUll are Jordi Carrer and Rafel Bru Gibert. Jordi Carrer is the CEO of DeepUll.

Here are the details of DeepUll's key team members:

Jordi Carrer: Co-Founder & CEO of DeepUll.
Rafel Bru Gibert: Co-Founder of DeepUll.

View details of DeepUll's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DeepUll include OpGen, CytoVale and Volition. Here is the list of Top 10 competitors of DeepUll, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	69/100
2nd	CytoVale 2013, San Francisco (United States), Series D	Microfluidic-based biomarkers for the early detection of sepsis	$207M	Norwest, Sands Capital & 20 others	63/100
3rd	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
4th	Earth Science tech 2014, Doral (United States), Public	Developer of a medical device for detection of chlamydia	-	-	54/100
5th	DNA Electronics 2003, London (United Kingdom), Series C	Developer of semiconductor‑based DNA‑sequencing systems for use in healthcare	-	Citi, Imperial Innovations & 1 others	54/100
6th	Bluejay Diagnostics 2015, Acton (United States), Public	Non-invasive point-of-care diagnostic solutions	$3.73M	Centrecourt Asset Management	50/100
7th	Abionic 2010, Epalinges (Switzerland), Series C	Provider of point-of-care diagnostic tool for allergy profiles	$28.9M	Venture Kick, MedHoldings & 17 others	49/100
8th	Avails Medical 2013, Menlo Park (United States), Series A	Rapid AST technology for faster, actionable results in bloodstream infections	$8.66M	CARB-X, Linden3 Ventures & 4 others	49/100
9th	HandyLab 1999, Ann Arbor (United States), Acquired	Developer of molecular diagnostic assays and automation platforms	$44M	Dow Chemical Company, Ann Lurie & 7 others	48/100
10th	Q-linea 2008, Uppsala (Sweden), Public	Fully automated platforms for pathogen detection	$18.3M	Nxt2b, SwediaCapital & 2 others	48/100
17th	DeepUll 2020, Barcelona (Spain), Series C	Developer of diagnostic technology for rapid identification of sepsis-causing pathogens	$92.5M	Kurma Partners, Columbus Venture Partners ... & 14 others	42/100